A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effect of Tesaglitazar 1 mg once daily on the Pharmacokinetics of Metformin Following Addition of Tesaglitazar to Metformin IR Treatment twice daily in Patients with Type 2 Diabetes

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting [email protected].

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting [email protected].